Previous 10 | Next 10 |
Cinedigm (NASDAQ: CIDM ) +139% on partnering with Vewd for global OTT channel distribution. More news on: Cinedigm Corp., Kezar Life Sciences, Inc., LiveXLive Media, Inc., Stocks on the move, , Read more ...
Thinly traded micro cap Kezar Life Sciences (NASDAQ: KZR ) jumps 57% premarket on increased volume on the heels of updated data from the first part of a Phase 1b/2 clinical trial, MISSION , evaluating candidate KZR-616 in patients with systemic lupus erythematosus (SLE) with a...
Gainers: LUB +115% . KZR +58.3% . ZUO +18.3% . ATSG +14.5% . IEC +12.3% . More news on: Luby's, Inc., Kezar Life Sciences, Inc., Zuora, Inc., Stocks on the move, , News on ETFs Read more ...
Two of two patients with Lupus Nephritis saw greater than 50% reduction in proteinuria KZR-616 demonstrates improvement on exploratory efficacy measures across seven measures of disease activity Step-up dosing drives positive safety and tolerability profile SOUTH SAN ...
SOUTH SAN FRANCISCO, May 28, 2020 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, today announced members of its executive t...
SOUTH SAN FRANCISCO, Calif., May 20, 2020 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR ), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmune disease and cancer, today announced pre...
Kezar Life Sciences (NASDAQ: KZR ): Q1 GAAP EPS of -$0.30 beats by $0.10 . Cash, cash equivalents and marketable securities of $123M Press Release More news on: Kezar Life Sciences, Inc., Earnings news and commentary, Healthcare stocks news, ,
Noreen R. Henig, MD appointed as Chief Medical Officer Additional data from the ongoing Phase 1b portion of the MISSION study to be presented before the end of Q2 2020 IND submission for KZR-261, a first-in-class protein secretion inhibitor, is on track for Q1 2021 Cash, ca...
A civilization is not destroyed by wicked people; it is not necessary that people be wicked but only that they be spineless." - James Baldwin Today, we take an in-depth look at a 'Busted IPO' whose stock has behaved better of late. This concern has several important trial milestones on t...
SAN FRANCISCO, May 04, 2020 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, today announced the appointment of Noreen R...
News, Short Squeeze, Breakout and More Instantly...
Kezar Life Sciences Inc. Company Name:
KZR Stock Symbol:
NASDAQ Market:
Kezar Life Sciences Inc. Website:
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer, today announced that Chris Kirk, Co-founder and Chief Executive Officer, will participate in a fireside chat at...
PALIZADE Phase 2b clinical trial of zetomipzomib in patients with active lupus nephritis actively enrolling; reiterating guidance of topline data in mid-2026 PORTOLA Phase 2a clinical trial of zetomipzomib in patients with autoimmune hepatitis actively enrolling; reiterating guidance of t...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...